Send better emails

MailCharts puts competitor emails and actionable data all in one place, so you can keep your inbox clutter-free. Learn more

From MRK Investor Relations <noreply@merck.com> Wednesday, Mar 12th, 2025 at 11:27 am

Subject: Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48

Preview text: Merck & Co., Inc., Rahway, New Jersey, USA (the company) has added a news r

Recent emails from Merck & Co